Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1985 1
1986 1
1987 3
1988 3
1989 3
1990 2
1991 3
1992 1
1993 3
1994 7
1995 6
1996 4
1997 3
1998 5
1999 5
2000 6
2001 1
2002 5
2003 5
2004 3
2005 7
2006 8
2007 8
2008 5
2009 10
2010 5
2011 9
2012 14
2013 15
2014 12
2015 11
2016 20
2017 10
2018 14
2019 17
2020 16
2021 11
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

250 results
Results by year
Filters applied: . Clear all
Page 1
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, Pisano C, Lapresa MT, Savarese A, Tagliaferri P, Lombardi D, Cinieri S, Breda E, Sabatucci I, Sabbatini R, Conte C, Cecere SC, Maltese G, Scambia G. Lorusso D, et al. Among authors: tagliaferri p. Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31. Gynecol Oncol. 2019. PMID: 31677820 Clinical Trial.
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.
Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N. Morelli E, et al. Among authors: tagliaferri p. Cancers (Basel). 2020 Jan 30;12(2):320. doi: 10.3390/cancers12020320. Cancers (Basel). 2020. PMID: 32019064 Free PMC article. Review.
Mouse models of multiple myeloma: technologic platforms and perspectives.
Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P. Rossi M, et al. Among authors: tagliaferri p. Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Oncotarget. 2018. PMID: 29732008 Free PMC article. Review.
The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: tagliaferri p. Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Expert Rev Hematol. 2018. PMID: 30148649 Review.
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L, Caraglia M, Botta C, Tagliaferri P. Correale P, et al. Among authors: tagliaferri p. Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9. Immunotherapy. 2019. PMID: 31865873 Free article. No abstract available.
Mir-221/222 are promising targets for innovative anticancer therapy.
Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: tagliaferri p. Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Expert Opin Ther Targets. 2016. PMID: 26959615 Review.
Mir-34: a new weapon against cancer?
Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Misso G, et al. Among authors: tagliaferri p. Mol Ther Nucleic Acids. 2014 Sep 23;3(9):e194. doi: 10.1038/mtna.2014.47. Mol Ther Nucleic Acids. 2014. PMID: 25247240 Free PMC article. Review.
250 results